Prospects of implementing programs for cardiovascular risk prevention among working age males

UDC: 
616.1 – 036.3 – 053.88 – 055.1 – 084
DOI: 
10.21668/health.risk/2026.2.10.eng
Authors: 

А.Е. Nosov1, О.Yu. Ustinova1,2, Iu.А. Petukhova3

Organization: 

1Federal Scientific Center for Medical and Preventive Health Risk Management Technologies, 82 Monastyrskaya Str., Perm, 614045, Russian Federation
2Perm State University, 15 Bukireva Str., Perm, 614068, Russian Federation
3Academician E.A. Vagner’s Perm State Medical University, 26 Petropavlovskaya Str., Perm, 614000, Russian Federation

Abstract: 

Management of risk factors (RF) that covers both risk control and mitigation is the most effective prevention of cardi-ovascular diseases (CVD).

The aim of this study was to investigate prevalence of CVD RF and potential effectiveness of preventive activities aimed at mitigating cardiovascular risks (CVR) among working age males.

We examined 152 working age males aged 45.0 (39.0; 50.0) years. The total group was divided into four subgroups depending on the number of RF: smoking, elevated systolic blood pressure (SBP), and dyslipidemia. CVR and potential effects gained by RF correction were calculated using the LIFE-CVD2 risk model.

We established high RF prevalence in the total group: 38.8 % of the participants smoked, 67.8 % had fat metabolism disorders, 26.9 % had elevated SBP and more than 70 % had dyslipidemia. Inter-group variability between Groups 1 and 4 was established for CVR itself, a potential decline in it due to therapy, as well as for the number of people who should undergo some interventions to prevent a cardiovascular event (NNT). High CVR value is directly proportionate to the number of added years of life and is inversely proportionate to the cardiovascular NNT. WE found a decline in CVR due to RF correction. In the high risk group, we can expect up to 14.75 (12.6; 16.06) added years of life at NNT = 3 (2; 3) due to therapy.

Therefore, high CVD RF prevalence persists among working age males. Prevention programs will allow avoiding CVD or CVD-caused deaths in 3.3 people in the total group (between 1.3 and 11.8 people) for 10 years per each 100 people. Long-term use of prevention to mitigate lifelong risk per each 100 people in the total group will make it possible to avoid cardiovascular events in 20 people (between 11.1 and 33.3 people) depending on a risk group.

Keywords: 
cardiovascular diseases, risk factors, working age males, life expectancy, smoking, systolic blood pressure, dyslipidemia, primary prevention
Nosov А.Е., Ustinova О.Yu., Petukhova Iu.А. Prospects of implementing programs for cardiovascular risk prevention among working age males. Health Risk Analysis, 2026, no. 2, pp. 107–115. DOI: 10.21668/health.risk/2026.2.10.eng
References: 
  1. Kakorina E.P., Nikitina S.Y. Features of the structure of mortality in the Russian Federation. Problemy sotsialnoi gi-gieny, zdravookhraneniya i istorii meditsiny, 2019, vol. 27, no. 5, pp. 822–826. DOI: 10.32687/0869-866X-2019-27-5-822-826 (in Russian).
  2. Boytsov S.A., Pogosova N.V., Ansheles A.A., Badtieva V.A., Balakhonova T.V., Barbarash O.L., Vasyuk Yu.A., Gambaryan N.G. [et al.]. Cardiovascular prevention 2022. Russian national guidelines. Rossiiskii kardiologicheskii zhurnal, 2023, vol. 28, no. 5, pp. 5452. DOI: 10.15829/1560-4071-2023-5452 (in Russian).
  3. Mamedov M.N. Global dynamics of mortality from cardiovascular diseases in different regions of the world. Mezhdunarodnyi zhurnal serdtsa i sosudistykh zabolevanii, 2025, vol. 13, no. 46, pp. 5–11. DOI: 10.24412/2311-1623-2025-46-5-11 (in Russian).
  4. Boytsov S.A., Shalnova S.A., Deev A.D. Cardiovascular mortality in the Russian Federation and possible mechanisms of its changes. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2018, vol. 118, no. 8, pp. 98–103. DOI: 10.17116/jnevro201811808198 (in Russian).
  5. Maslennikova G.Ia., Oganov R.G., Drapkina O.M. Modern global, regional and national priority strategic directions for the prevention and control of noncomminicable diseases. Profilakticheskaya meditsina, 2020, vol. 23, no. 2, pp. 7–12. DOI: 10.17116/profmed2020230217 (in Russian).
  6. Galimzyanov A.F., Khayrullin R.N., Garipov R.Z., Slater M., Galiullin D.A., Aminov D.D. Methodological framework for the management and mitigation of cardiovascular disease risk factors. Profilakticheskaya meditsina, 2022, vol. 25, no. 3, pp. 36–46. DOI: 10.17116/profmed20222503136 (in Russian).
  7. Drapkina O.M., Kontsevaya A.V., Kalinina A.M., Avdeev S.M., Agaltsov M.V., Alexandrova L.M., An¬tsiferova A.A., Aronov D.M. [et al.]. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Kardiovaskulyarnaya terapiya i profilaktika, 2022, vol. 21, no. 4, pp. 3235. DOI: 10.15829/1728-8800-2022-3235 (in Russian).
  8. Budreviciute A., Damiati S., Sabir D.K., Onder K., Schuller-Goetzburg P., Plakys G., Katileviciute A., Khoja S., Ko-dzius R. Management and Prevention Strategies for Non-communicable Diseases (NCDs) and Their Risk Factors. Front. Public Health, 2020, vol. 8, рр. 574111. DOI: 10.3389/fpubh.2020.574111
  9. Kelishadi R. Life-Cycle Approach for Prevention of Non Communicable Disease. Adv. Exp. Med. Biol., 2019, vol. 1121, рр. 1–6. DOI: 10.1007/978-3-030-10616-4_1
  10. Mikkelsen B., Williams J., Rakovac I., Wickramasinghe K., Hennis A., Shin H.-R., Farmer M., Weber M. [et al.]. Life course approach to prevention and control of non-communicable diseases. BMJ, 2019, vol. 364, рр. l257. DOI: 10.1136/bmj.l257
  11. Boytsov S.A. Prevalence of cardiovascular risk factors and cardiovascular prevention quality in primary healthcare in Russia and European countries: EURIKA Study results. Kardiovaskulyarnaya terapiya i profilaktika, 2012, vol. 11, no. 1, pp. 11–16. DOI: 10.15829/1728-8800-2012-1-11-16 (in Russian).
  12. Kobiakova O.S., Deev I.A., Kulikov E.S., Starovoytova E.A., Malykh R.D., Balaganskaya M.A., Zagromova T.A. Chronic noncommunicable diseases: combined effects of risk factors. Profilakticheskaya meditsina, 2019, vol. 22, no. 2, pp. 45–50. DOI: 10.17116/profmed20192202145 (in Russian).
  13. Chulkov V.S., Gavrilova E.S., Chulkov V.S., Pankova E.D., Lenets E.A., Tkachenko P.E. Primary prevention of car-diovascular disease: focus on improving behavioral risk factors. Rossiiskii kardiologicheskii zhurnal, 2021, vol. 26, no. 3S, pp. 4278. DOI: 10.15829/1560-4071-2021-4278 (in Russian).
  14. Kontsevaya A.V., Mukaneeva D.K., Ignatieva V.I., Antsiferova A.A., Drapkina O.M. Economics of cardiovascular prevention in the Russian Federation. Rossiiskii kardiologicheskii zhurnal, 2023, vol. 28, no. 9, pp. 5521. DOI: 10.15829/1560-4071-2023-5521 (in Russian).
  15. Mocumbi A.O. Cardiovascular Health Care in Low- and Middle-Income Countries. Circulation, 2024, vol. 149, no. 8, рр. 557–559. DOI: 10.1161/CIRCULATIONAHA.123.065717
  16. Zimakova E.I., Orlova I.A., Begrambekova Yu.L. Prevalence and perspective directions for correction of behavioral risk factors of cardiovascular diseases associated with unhealthy diet and low physical activity in young people.
    Yuzhno-Rossiiskii zhurnal terapevticheskoi praktiki, 2024, vol. 5, no. 3, pp. 6–13. DOI: 10.21886/2712-8156-202-5-3-6-13 (in Russian).
  17. Ference B.A., Graham I., Tokgozoglu L., Catapano A.L. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. J. Am. Coll. Cardiol., 2018, vol. 72, no. 10, pp. 1141–1156. DOI: 10.1016/j.jacc.2018.06.046
  18. Khan S.S., Matsushita K., Sang Y., Ballew S.H., Grams M.E., Surapaneni A., Blaha M.J., Carson A.P. [et al.]. Development and Validation of the American Heart Association's PREVENT Equations. Circulation, 2024, vol. 149, no. 6, pp. 430–449. DOI: 10.1161/CIRCULATIONAHA.123.067626
  19. Zuin M., Bilato C., Temporelli P.L. Novel Concepts for the Estimation of Lifetime Cardiovascular Risk. High Blood Press. Cardiovasc. Prev., 2025, vol. 32, no. 4. pp. 387–395. DOI: 10.1007/s40292-025-00724-x
  20. Hageman S.H.J., Kaptoge S., de Vries T.I., Lu W., Kist J.M., van Os H.J.A., Numans M.E., Läll K. [et al.]. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions. Eur. J. Prev. Cardiol., 2024, vol. 31, no. 14, pp. 1690–1699. DOI: 10.1093/eurjpc/zwae174
  21. Yusuf S., Joseph P., Rangarajan S., Islam S., Mente A., Hystad P., Brauer M., Raman Kutty V. [et al.]. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet, 2020, vol. 395, no. 10226, рр. 795–808. DOI: 10.1016/S0140-6736(19)32008-2
Received: 
25.03.2026
Approved: 
06.05.2026
Accepted for publication: 
27.06.2026

You are here

Home